Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

Documenti analoghi

• Hypercalcemia as an Immune‐Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
  di: Sam Plessers, et al.
  Pubblicazione: (2025)
• Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy
  di: Yoshie Mita, et al.
  Pubblicazione: (2025)
• Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC
  di: Xin Xiang, et al.
  Pubblicazione: (2026)
• Response: Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC
  di: Jung Sun Kim, et al.
  Pubblicazione: (2026)
• Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response
  di: Ethan Trim, et al.
  Pubblicazione: (2025)